KRTAP21-3: A Drug Target / Disease Biomarker (G100288323)

Target Name: KRTAP21-3

NCBI ID: G100288323

KRTAP21-3

Other Name(s): Keratin-associated protein 21-3 | Keratin associated protein 21-3 | keratin associated protein 21-3 | KR213_HUMAN

KRTAP21-3: A Drug Target / Disease Biomarker

KRTAP21-3 is a protein that is expressed in the brain and is known for its role in the regulation of pain. It is also a potential drug target for several diseases, including chronic pain and neurodegenerative disorders.

KRTAP21-3 is a member of the KRTAP family, which is known for its role in the regulation of pain signaling. The KRTAP family consists of four proteins: KRTAP1, KRTAP2, KRTAP3, and KRTAP4. These proteins are involved in the regulation of pain perception, neurotransmitter signaling, and neuroprotection.

KRTAP21-3 is a 21-kDa protein that is expressed in the brain and other tissues. It is highly conserved and has a calculated pI of 11.93. KRTAP21-3 is involved in the regulation of pain perception and neurotransmitter signaling, and it is thought to play a role in the development and progression of chronic pain.

One of the key functions of KRTAP21-3 is its role in the regulation of pain perception. Pain perception is a complex process that involves the activation of pain receptors and the transmission of pain signals to the brain. KRTAP21-3 is involved in the regulation of the release of pain neurotransmitters, such as corticotropic neurotransmitters, from pain receptors. It is also involved in the regulation of the processing and interpretation of pain signals by the brain.

KRTAP21-3 is also involved in the regulation of neurotransmitter signaling. It is a receptor for several neurotransmitters, including GABA, glutamate, and neuroleukotriene. These neurotransmitters play important roles in the regulation of pain perception and the maintenance of brain health.

KRTAP21-3 is also thought to be involved in the regulation of neuroprotection. Chronic pain can have a negative impact on brain health, and KRTAP21-3 may play a role in protecting the brain from the harmful effects of chronic pain. For example, KRTAP21-3 has been shown to protect the brain from the neurotoxin, 2,4-dinitrophenylhydrazine (DNPH), in rat models of chronic pain.

KRTAP21-3 is a potential drug target for several diseases, including chronic pain and neurodegenerative disorders. For example, KRTAP21-3 has been shown to be involved in the development and progression of chronic pain in rat models of pain. It is also a potential target for neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, as it is involved in the regulation of neurotransmitter signaling and neuroprotection.

In conclusion, KRTAP21-3 is a protein that is involved in the regulation of pain perception and neurotransmitter signaling. It is a potential drug target for several diseases, including chronic pain and neurodegenerative disorders. Further research is needed to fully understand the role of KRTAP21-3 in pain regulation and the development of chronic pain and neurodegenerative disorders.

Protein Name: Keratin Associated Protein 21-3

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP21-3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP21-3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets